Compare abrdn Physical Palladium Shares ETF (PALL) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
abrdn Physical Palladium Shares ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? abrdn Physical Palladium Shares ETF trades at $24.5, while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals.
| PALL | VRTX | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $37.18 | $557.96 |
52-Week Low | $20.97 | $376.62 |
Market Cap | — | $134.06B |
Enterprise Value | — | $128.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PALL, the Aberdeen Physical Palladium Shares ETF, trades at $24.43, down 3.48% over 24 hours. Technical indicators are bearish, with moving averages signaling sell pressure, while oscillators are neutral. Recent news highlights palladium's underperformance relative to other precious metals, with some analysts viewing current price weakness as a potential buying opportunity due to supply risks and industrial demand.
The outlook for PALL hinges on palladium's supply-demand dynamics and broader commodity trends. Investment opportunities exist if palladium prices rebound from support levels, but risks include continued commodity volatility and macroeconomic pressures affecting industrial demand.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
